INTRODUCTION
Although the discovery of the etiological agent of AIDS (human immunodeficiency virus [HIV] ) is relatively recent, the wealth of information associated with this virus has far surpassed that for any other known human retrovirus. Yet, despite this growing body of knowledge, many aspects about the life cycle of HIV remain to be elucidated. The regulation of HIV gene expression is a tightly controlled process in which cellular and viral factors participate to allow the differential and temporal expression of viral gene products, a number of which are not found in most other animal retroviruses. In particular, two HIV regulatory genes, tat and rev, play key roles in the HIV life cycle and may provide attractive targets for antiviral therapy. Furthermore, their mechanisms of action are entirely novel and may be important paradigms of eukaryotic gene regulation.
REPLICATION OF HIV
The life cycle of HIV is similar to that of other known animal retroviruses. The progressive immunodeficiency of the disease is characterized by depletion of CD4+ helper/ inducer lymphocytes, at least partially resulting from the tropism of HIV for the CD4+ subset of T lymphocytes and its cytopathic effect (61) . HIV tropism appears to be restricted at the stage of viral entry since transfection of * Corresponding author.
human and animal fibroblasts with viral DNA led to the generation of infectious virus (26, 63) . Upon binding and adsorption into the target cell, HIV initiates the processes of uncoating, reverse transcription, and integration. The newly integrated proviral DNA thus persists and becomes part of the genetic endowment of the host cell. The propensity for HIV to establish a latent infection within the host is a hallmark of all the human T-lymphotropic retroviruses, which could remain hidden inside the very cells which are responsible for cell-mediated immunity against virus infection. The (67, 110) . Most (38) . Point mutations within the SPl-binding sites between -46 and -66 greatly reduced the rate of transcription both in vitro and in vivo (57) , suggesting that viral transcription may be partially dependent on the interactions of SP1 with the HIV LTR. The enhancer element located between positions -109 and -79 contains two imperfect repeat sequences which have been shown to stimulate the rate of RNA transcription initiation from the LTR (89) . Contained within the enhancer is the consensus recognition sequence for the DNA-binding protein NFKB (76) , the activated T-cell protein HIVEN86A (34) , and an additional enhancer-binding protein, termed EBP-1 (121) . NFKB, an inducible transcription factor expressed in immunoglobulin-producing B cells, has also been found to be expressed in activated T cells and macrophages. This protein may impart a novel activation signal by which HIV-infected T cells, upon mitogenic stimulation, begin virus production. The interaction between NFKB and the HIV enhancerlike sequence may activate HIV gene expression by binding and initiating viral transcription from the LTR by a mechanism not unlike that proposed for the transcriptional activation of interleukin-2 (IL-2) and the IL-2 receptor a subunit (6) . Thus, the potential interaction of NFkB and the enhancer-binding site may provide a clue to the activation of virus production seen in infected T cells in vivo.
Additional DNA-binding proteins have been identified which bind to the upstream LTR region. The nuclear factor of activated T cells (NFAT-1), AP-1, and upstream binding factor bind to the 5' region of the LTR which also contains the negative regulatory element (35, 38, 103) . The NRE, located at positions -420 and -159, functions to downregulate the rate of transcription. Deletions within this region have led to higher virus production in CD4+ T lymphocytes (64) , suggesting that certain cellular proteins bound to this region may have an inhibitory function on viral transcription. Three DNA-binding proteins which bind to the 5' untranslated leader region have also been identified.
CTF/NF-1 and leader-binding protein (LBP-1) are cellular transcription factors which interact with sequences immediately downstream from the mRNA start site to enhance transcription (58) . LBP-1 has three distinct binding sites at positions -3 to +2, +8 to +12, and +28 to +32, suggesting a possible role in correctly initiating RNA transcription from the LTR. The trans-activation response sequence (TAR)-binding protein UBP-1 binds directly to the TATA box homology through the start of transcription to +44 and may function in the transcriptional activation of HIV gene expression (121) . The complement of cellular factors that interact with the HIV LTR and regulate its expression is far from being fully delineated. It is expected that the variety and abundance of these factors will vary according to cell types (e.g., T lymphocytes versus monocytes) and cell cycle. The interplay of these cellular factors and viral trans-acting factors will determine the level of virus expression and ultimately the clinical course of infection.
MOLECULAR STRUCTURE OF THE HIV GENOME
Although expression of the simpler type C retroviruses is regulated predominantly by cellular factors impacting on the viral LTR, the human retroviruses and their animal counterparts also encode trans-acting viral regulatory factors. The organization of the HIV genome is now well defined (Fig. 2) . HIV contains the three essential genes common to all retroviruses: gag, pol, and env flanked by the LTR promoter and enhancer regions. The gag gene encodes the virion proteins which form the inner matrix of the mature virus particle. The Gag polyprotein precursor p55 is cleaved during virus maturation, yielding several smaller proteins which include p17 (myristylated Gag protein), p24 (major core antigen), p7 (nucleoprotein), and p9 (nucleocapsid protein). The pol gene is expressed from a gag-pol polyprotein precursor, formed by a ribosomal frameshifting event mediated by a sequence located in the gag-pol overlap. A -1 shift in the reading frame allows the ribosomes to continue translation through the UAG termination site on the gag reading frame (55, 118) . The subsequent cleavage of the gag-pol precursor gives rise to three enzymes, protease, reverse transcriptase, and integrase, which are all necessary for viral replication. The env gene encodes the envelope proteins found on the surface of the virus particle which are necessary for binding and entry into the host cell. The Env precursor protein gpl60 is heavily glycosylated and is processed through a critical endoproteolytic cleavage, forming the major envelope glycoprotein gpl20 and the small transmembrane envelope protein gp4l (73) .
Along with the structural genes of HIV are at least six additional accessory genes whose functions impart both positive and negative effects on the HIV life cycle. The gene products of tat, rev, nef, and vpr potentially contribute to regulation of viral gene expression in both a positive and a negative manner. Tat and Rev are novel in their transactivating functions, using cis-acting sequences found in RNA, rather than DNA, as their targets for trans-activation. Tat, which has been shown to be absolutely essential for virus replication, acts as a central switch which initiates the expression of all viral genes. However, the actual mechanism of trans-activation remains controversial and will be discussed in detail later. Rev, also an essential viral protein, functions to control the differential expression of both spliced and unspliced viral mRNAs, thereby allowing the accumulation and nuclear export of mRNAs encoding the structural genes necessary for virus assembly. Nef was originally thought of as a negative regulator of expression; however, its actual function during viral replication has come under intense scrutiny recently. Previous reports have shown that mutations in nef resulted in an approximate 10-fold increase in viral replication, suggesting that Nef may lower all viral gene expression by acting as a silencer. In contrast, other investigators have shown that although Nef is dispensable for virus replication, mutations within the gene do not give rise to an increase in viral replication. There are preliminary reports that Nef may function as a necessary factor for virus growth in primary monocytes and macrophages, providing the tropism for productive infection in these particular cell types (46a) and that a functional nefgene is highly selected for in monkeys infected with the simian immunodeficiency virus (SIV) (21a (14) and is expressed as a Tat-T fusion protein through a ribosomal frameshift. The consensus "slippage" sequence is highly conserved among HIV-1 isolates, and the protein is made in in vitro translation systems. However, there is no evidence that this protein is expressed in vivo. Also unique to HIV-1 is the tev reading frame generated from a spliced mRNA which encodes a 28-kDa protein consisting of coding sequences from tat, env, and rev (2, 98) . The chimeric protein is bifunctional and exhibits both Tat and Rev activities. Table 1 summarizes some of the properties of these genes and their products.
MECHANISMS OF Tat trans-ACTIVATION Functional Domains of Tat
The first indication that HIV-1 encoded trans-acting regulatory genes was the demonstration that HIV-infected cells are capable of stimulating LTR-directed gene expression (108) . This activity was later mapped to the tat gene (1, 107) . Tat is a powerful trans-activator of viral gene expression and is essential for virus growth (20, 31, 94) . The tat gene codes for an 86-amino-acid protein which is localized in the nucleus and concentrated predominantly in the nucleolus of the infected cell (51, 93) . The tat mRNA is generated from multiple splicing events and is composed of at least three species. The most common form is a tripartite mRNA consisting of a first exon derived from the 5' untranslated sequence, a coding exon for the first 72 amino acids of the protein, and a second coding exon for the last 14 amino acids (1) . Additional species may contain upstream noncoding exons derived from the pol gene. Deletion analysis has revealed that the amino-terminal 58 amino acids in the first coding exon of tat is sufficient for trans-activation, albeit with reduced activity (104) . The 58 amino acids of Tat contain three essential functional domains. The acidic amino-terminal domain of Tat consists of two glutamate residues and one aspartate residue at positions 2, 5, and 8 which are critical for trans-activation function (86) . The location of these acidic residues is consistent with the formation of an amphipathic a-helix, which may be important for efficient trans-activation (42) . Exchanging the entire domain with heterologous sequences which have the potential to form an acidic, amphipathic a-helix partially restored activity. A stretch of seven cysteine residues makes up the second domain. It is believed that this region is necessary for zinc ion-mediated dimerization of the Tat protein (32) . Missense mutations within this cysteine-rich region have shown that all residues but one are critical for activity (37, 50, 93, 95) . The carboxy-terminal domain consists of a stretch of basic amino acids (residues 49 to 57) necessary for nuclear localization (50, 93) . Point mutations within this cluster of positively charged amino acids resulted in the accumulation of nonfunctional Tat protein in the cytoplasm. When placed within heterologous cytoplasmic proteins, the nuclear localization signal, GRKKR, can impart properties of nuclear localization to these proteins (93) . Recently it was shown that a peptide containing the basic domain of Tat bound specifically to its RNA target, TAR (for trans-activation response sequence) in vitro, suggesting that this domain may serve not only to localize the protein to the nucleolus but also to interact specifically with TAR (91).
Tat and TAR Interactions trans-activation by Tat requires a specific recognition of this effector protein with a target sequence, TAR, contained in the R region of the viral LTR (89). Thus, unlike many of the enhancer sequences and transcription factor-binding sites which are located upstream from the start of transcription, the TAR sequence is located in a region of the LTR which is transcribed. Extensive mutagenesis of this region has found that the sequences located between +1 and +42 with respect to the initiation site of viral transcription are those necessary for Tat responsiveness (49, 56, 75) . The position and orientation of the TAR element is also critical for its function; inversion of the sequence or an increased spatial arrangement between TAR and the start of transcription diminishes Tat trans-activation activity (56, 75, 100).
The RNA encoded by TAR between +1 and +111 has the potential to form one or more stem-loop secondary structures which would be found in all newly transcribed viral mRNAs (75) . Feng and Holland (29) have described experiments using nucleotide substitutions and shown that Tat trans-activation requires the presence of the sequence CUGGG (positions +30 to +34) within the first TAR RNA stem-loop structure. A more extensive analysis of the TAR hairpin structure has revealed a three-nucleotide bulge at the base of the hairpin which also seems critical, as mutations within this bulge dramatically reduce Tat trans-activation (4, 92) . In contrast, mutations that altered the sequence but not the structure of the stem-loop had no effect on Tat responsiveness, suggesting that TAR may function as RNA, rather than DNA. This was further substantiated by Berkhout et al. (5), who showed that directing changes outside the TAR sequence which would prevent formation of the stem-loop in newly transcribed TAR RNA also effectively abolished tat responsiveness. Therefore, Tat must recognize the correct secondary stem-loop structure in the nascent RNA to execute its function.
Recently, purified Tat has been shown to interact directly with TAR RNA, but not TAR DNA (23, 91) . Additionally, a single uridine nucleotide change within a three-nucleotide bulge structure (positions +23 to +25) of the TAR RNA stem-loop was sufficient to abolish both Tat binding and trans-activation (91). However, it appears that Tat responsiveness may not depend on the ability of the protein to bind the TAR RNA sequence alone. Deletions within the TAR RNA structure which have been shown to abolish Tat activity in vivo (92) did not disrupt Tat binding to this sequence in vitro. Therefore, additional regulatory factors must be required for trans-activation. Several groups have shown that cellular proteins recognize and bind TAR RNA. Two distinct host proteins isolated from HeLa cell nuclei bind specifically to TAR RNA as a complex (39, 40) . Also, a 68-kDa protein purified from HeLa cell nuclei has shown RNA-binding specificity to TAR (71) . Host factors which bind purified Tat in a protein-protein complex have also been identified. Two such proteins have been obtained from a eukaryotic protein expression library (78) . Lastly, human chromosomes encoding host factors which may play a role in Tat trans-activation have been identified by using rodenthuman hybrid cells (46, 81) . The effects of Tat transactivation on the HIV-1 LTR, normally reduced in rodent cell lines, was greatly increased by the addition of human chromosome 12 into the hybrid cells, further emphasizing the importance of host cellular factors which may contribute to the Tat trans-activation response.
Transcriptional and Posttranscriptional Activation by Tat Although many aspects of the Tat protein have been studied in detail, the mechanism of Tat trans-activation remains unclear. All researchers agree that Tat activates viral gene expression from the LTR and thus acts as the central control switch for HIV replication. Initial studies suggested that Tat dramatically stimulates LTR-directed protein expression with only a slight increase in steady-state mRNA levels (26, 88) . However, some studies also suggested that transcriptional activation alone can account for the observed stimulation of protein expression (51, 56, 62, 75, 85, 87, 120) . The current consensus is that Tat activates at both transcriptional and posttranscriptional levels (16) and that the contribution of each component may depend on the nature of the target cell. The location of TAR near the start of transcription initiation in the DNA and the 5' cap site in the viral mRNA makes such a bimodal mechanism feasible.
At the level of transcription, it has been proposed that Tat acts primarily as an antiterminator of RNA elongation (59 (26, 54, 69, 106) . In the absence of Rev or Rex, the only viral RNA species which accumulate in the cytoplasm are multiply spliced and encode only a subset of the viral regulatory proteins.
Rev Protein
The rev gene was originally discovered within the two tat coding exons after mutational analyses revealed that some deletions either within or near the tat sequences could not be complemented by functional tat cDNA clones (26, 106) . The rev coding sequence is composed of several mRNA species that encode a protein consisting of 116 amino acids (26, 94) . Rev is a 19-kDa phosphoprotein located predominantly in the nucleolus of the cell (13, 17, 27) . At least two serine residues have been shown to be phosphorylated in vivo (48) ; however, phosphorylation of Rev appears to be nonessential for activity (68) . Two distinct motifs critical for function have been identified on the Rev protein. A short basic stretch of amino acids at the amino terminus (residues 40 to 45) has been shown to be important for nuclear, and specifically nucleolar, localization (13, 68) . Some mutations within the basic sequence resulted in the accumulation of inactive Rev protein in the nucleus, but not in the nucleolus (13, 115 (69, 90) . The location of the RRE within the gag-pol and env mRNAs further supports the working hypothesis that Rev functions as a posttranscriptional regulator of virus expression. RRE has been functionally defined to be a sequence of about 200 nucleotides (21, 83) . This sequence on the RNA is predicted to form a complex secondary structure composed of five stem-loops (70, 83) . Within this structure the most important determinant for Rev responsiveness was shown to be stem-loop 11 (70) . Stem-loop II resembles a hammerheadlike configuration which can be subdivided into stem-loops IIA and IIB. Deletion mapping studies of the RRE secondary structure has revealed that deletions within stem-loop II or IIA abolish RRE activity while stem-loops III, IV, and V were dispensable for function (70) . Deletions within stemloop I reduced but did not abolish activity. The importance of these stem-loop structures is also consistent with the observation that the integrity of the secondary structure, rather than the primary nucleotide sequence, is the determining factor for Rev-RRE interactions (22, 83) .
Purified Rev specifically binds to the RRE RNA in vitro (12, 18, 19, 52, 70, 83, 123) . Mutational analysis suggested that stem-loop II is the major determinant for Rev interaction, consistent with the observation that stem-loop II is also critical for the Rev response in vivo (70, 83) . Daefler et al. found that the first 90 nucleotides of the RRE are sufficient for direct Rev interaction (18) . Although this sequence does not contain an intact stem-loop II, it may refold to a secondary structure which mimics the hammerhead configuration in this region (114a) . Rev interacts with RRE as a multimer. It is possible that multimerization is necessary in Rev function (82) .
Mechanism of Rev Regulation: Splicing versus Transport As briefly alluded to above, the regulation of viral RNA expression is greatly influenced by the action of Rev. In the course of an infection, the first appearance of the smaller (1.8-to 2-kb) multiply spliced RNAs in the cytoplasm coincides with the synthesis of the regulatory but not structural proteins. Over a period (usually within 24 h) there is a shift in the accumulation of the larger (4.3-to 9.2-kb) unspliced or singly spliced mRNAs which provide the templates for production of the full complement of virus structural proteins. This pattern of temporal expression during infection has recently been described (60, 119) . When it was first observed that rev mutants expressed only multiply spliced mRNA and failed to accumulate the full-length and singly spliced RNA transcripts in the cytoplasm, it was proposed that Rev differentially regulated the splicing of viral mRNA (26, 94) . Whether such is the case is still controversial. Several studies showed that Rev can act on RRE-containing RNAs which lack functional splice sites (21, 27) . However, the possible involvement of cryptic splice sites has not been ruled out. Studies on the expression of chimeric globin-RRE pre-mRNA transcripts suggest that HIV-derived spliced sites were necessary for Rev function and response (11) . Furthermore, stable base-pairing of the 5' donor site to Ul RNA was also found to be important for Rev activation (45) . An alternative, but not mutually exclusive, role of Rev is at the level of nuclear export, where direct interaction of Rev and RRE could shunt RRE-containing mRNA from the nucleus to the cytoplasm. This is supported by findings that under some circumstances, the level of spliced and unspliced RNA in the nucleus remained unaffected by the presence or absence of Rev, but the cytoplasmic content of such mRNA was dramatically altered (27, 44, 69) . In this context, a repressive sequence that is found in the gag, pol, and env coding regions and is termed the cis-acting repressive sequence (90) may specifically trap RNA in the nucleus. Taken together, these findings suggest that Rev may circumvent spliceosome-mediated nuclear retention by binding to the RRE and disrupting the formation of spliceosomes, resulting in more efficient export of RREcontaining RNA to the cytoplasm (Fig. 4) .
Tat AND Rev AS TARGETS FOR ANTIVIRAL THERAPY
In Vitro Assays for Inhibitors The requirement for both Tat and Rev during virus replication offers the potential for development of specific antiviral strategies against HIV infection. Inhibiting the function of Tat and Rev during the initial stages of replication would most probably halt the generation of infectious viral progeny and subsequently stop any further infection of the target cell population. Two in vitro bioassay systems which may potentiate the screening of inhibitors effective against Tat have been described (28, 41) . Introducing Tat into an LTR-CAT indicator cell line preincubated with a potential inhibitor of Tat function may prove to be a model system for studying antiviral drugs which may interfere with trans-activation. The subsequent activation or repression of CAT gene expression thus provides a sensitive and rapid means of measuring the effectiveness of the drug on Tat trans-activation. A similar approach can be taken for Rev. A reporter gene construct containing RRE sequences and cis-acting repressive sequences would be dependent on a functional Rev protein for activity, and inhibitors could be screened with a stable cell line expressing the reporter gene and Rev.
Transdominant Mutants
The generation of a transdominant negative phenotype provides a novel approach for inhibiting the wild-type function of a gene within the cell (53) . Evidence for this proposal has been previously shown with a transdominant phenotype of the herpes simplex virus type 1 trans-activator VP16 (36 
Antisense Oligonucleotides
The use of antisense oligonucleotides as antiviral therapeutic agents is a relatively new approach to inhibit HIV infection. Antisense oligonucleotides derived from the initiation sequence of rev have been shown to be effective in blocking the expression of virus from chronically infected cells in a sequence-specific manner (72) . Despite the effectiveness of these oligonucleotides as virus inhibitors in vitro, many other factors must come into play before practical application: pharmacokinetic properties, toxicity, and cost effectiveness, to name a few. So far, no clinical tests targeting oligonucleotides to HIV-infected cells in vivo have been performed. EXPANDED REPERTOIRE OF Tat ACTIVITIES A number of recent studies suggest that Tat function is not restricted to activation of virus gene expression in the infected cell, but may also affect uninfected cells through release and uptake and may activate genes from heterologous promoters. Additionally, Tat may modulate cell proliferation and contributes to the progression of at least one malignancy, Kaposi sarcoma.
Uptake of Tat
Purified Tat protein added to the extracellular culture medium is taken up by cells and is able to trans-activate LTR-directed gene expression (33, 41) . Tat protein tagged by radioactivity or fluorescein conjugation binds to the cell surface in discrete regions and migrates to the nucleus and the nucleolus of treated cells (31a, 46a) . Binding of labeled Tat to the cell is very rapid and is not inhibited by excess unlabeled Tat, suggesting that Tat enters the cell via endocytosis in clathrin-coated pits rather than a specific cell receptor.
Extracellular Tat
Tat protein is present in the medium of HIV-1-infected cells and cells which have been transfected with tat DNA (24) . The amount of extracellular Tat observed under these conditions does not correlate directly with the amount of cell death. However, it cannot be entirely ruled out that the major source of extracellular Tat is derived from dying cells.
Alternatively, Tat protein may be actively secreted. Although Tat lacks a consensus signal peptide, a number of cytokines, including IL-1, IL-1,, and the acidic as well as basic fibroblast growth factors and platelet-derived endothelial growth factors can be exported from cells in the absence of a known secretory consensus signal peptide. Tat may be an additional protein excreted from cells by a mechanism as yet unknown. OPPORTUNISTIC VIRUSES AS COFACTORS Many opportunistic viruses have been implicated with a role in the promotion of AIDS in the HIV-infected individual (79) . Also, it has been suggested that viruses which cause severe opportunistic infections in AIDS patients may also serve as cofactors which initiate the onset of AIDS or accelerate the progression of the disease. The human T-leukemia viruses, HTLV-I and HTLV-II, which infect the same target cell as HIV, may play a role in reactivating HIV in the persistently infected T cell. Siekevitz et al. (105) and Bohnlein et al. (7) demonstrated that the HTLV-I transactivator gene tax could activate the HIV LTR, exerting its effect indirectly through an inducible cellular factor which interacts with the NFkB-binding site located in the LTR enhancer region. Coincidently, activation of the IL-2 receptor ax gene is also mediated through the interactions of these tax-inducible cellular factors with the NFkB-binding site located in the IL-2 receptor promoter region. This finding demonstrates the possibility of a unique overlap between two very different pathways of T-cell activation and HIV proliferation in infected T cells (6) . The HIV-1 provirus, normally quiescent within the T cell, would now be activated by HTLV-I Tax-induced cellular proteins which are normally involved in T-cell proliferation.
Several other DNA viruses which may permit reactivation of the HIV provirus have been examined. Herpes simplex virus type 1 and Human herpesvirus 6 (HHV-6), now commonly found in the same population at risk for HIV, have been shown to increase viral gene expression from the HIV LTR in vitro (25, 65, 74) . However, only HHV-6 shares the same tropism for the CD4+ target cell as HIV, which suggests that HHV-6 might contribute to the CD4+ depletion seen in AIDS patients. Lusso infected with HIV or HHV-6 alone. HHV-6 may increase the rate of HIV replication by acting directly on the HIV LTR, thereby increasing LTR-directed viral gene expression and subsequent cytopathic effect on the target cell population. However, it is not known whether the progression of AIDS increases in individuals coinfected with these viruses.
Another herpesvirus, human cytomegalovirus, has been detected in T lymphocytes during HIV infection (99) . It has also been found along with HIV in the brain tissues of AIDS patients (80) 
